The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03843346|
Recruitment Status : Active, not recruiting
First Posted : February 18, 2019
Last Update Posted : January 18, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
After a breast cancer and any lymph glands have been surgically removed, further (adjuvant) treatment is generally given to reduce the risk of cancer recurrence. For patients with estrogen receptor (ER) positive breast cancer, this treatment has traditionally been chemotherapy and hormone therapy. However, it is increasingly recognised that tumours which are ER positive and negative for the human epidermal growth factor receptor 2 (HER2), are relatively resistant to chemotherapy. It is likely that many more people are exposed to the risks for chemotherapy than ever benefit from it. In order to select patients who will get more benefit from chemotherapy and to spare those who get very little benefit from side effects, risk assessment tools are being developed.
The 21 Gene Recurrence Score is a test that examines the tumour genes to estimate the risk of the tumour relapsing and possible chemotherapy benefits. Currently, the 21 Gene Recurrence Score (OncotypeDx®) is used In Ireland for patients with no cancer in their lymph nodes. For these patients it can help in deciding who should get chemotherapy. Patients with low scores can sometimes avoid chemotherapy. In some countries, this test is offered to almost all patients with ER positive breast cancer, irrespective of whether the cancer has spread to lymph nodes or not. However, in Ireland this test is not standardly available for patients who have breast cancer involving lymph nodes.
|Study Type :||Observational|
|Actual Enrollment :||87 participants|
|Official Title:||The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy Prescribing in Estrogen Receptor Positive, Lymph Node Positive Early Stage Breast Cancer in Ireland|
|Actual Study Start Date :||March 16, 2017|
|Actual Primary Completion Date :||December 10, 2021|
|Estimated Study Completion Date :||February 2022|
Cohort 1: Postoperative group
Consists of 75 patients who have completed definite surgery for their primary breast cancer as determined by a Consultant Surgeon and have been referred to a Medical Oncologist for consideration of adjuvant chemotherapy.
Cohort 2: Preoperative group
Consists of 75 patients who have been referred by a Consultant Surgeon to a Medical Oncologist for consideration of neoadjuvant (preoperative) chemotherapy.
- Recommended Chemotherapy [ Time Frame: 3 years ]The percentage reduction in the number of patients for whom chemotherapy is recommended following resection of their primary breast cancer and testing with the 21 gene RS (cohort 1; n=75)
- Impact of gene RS [ Time Frame: 3 years ]Examine the impact of the 21 gene RS on chemotherapy recommendations in operable breast cancer in the postoperative and preoperative setting (cohorts 1 and 2; n=150) using questionnaires completed by Medical Oncologists.
- Complete Response [ Time Frame: 3 years ]Investigate the correlation between the 21 gene RS and pathological complete response from preoperative therapy in operable breast cancer (cohort 2; n=75).
- Radiological Response Rate [ Time Frame: 3 years ]Determine whether the 21 gene RS correlates with clinical, radiological response rate and the MD Anderson residual cancer burden score following preoperative therapy (cohort 2; n=75).
- Economic Impact [ Time Frame: 3 years ]Determine the economic impact of the 21 gene RS testing on ER positive, node positive breast cancer patients (cohorts 1 and 2; n=150) using a simple budget impact model
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Gender Based Eligibility:||Yes|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
The study will examine 2 cohorts of patients;
- 75 patients (cohort 1; "postoperative") who have undergone resection of their primary breast cancer and
- 75 patients (cohort 2; "preoperative") who are referred to a Medical Oncologist for consideration of neoadjuvant (preoperative) treatment.
Both cohorts will have ER positive, lymph node positive breast cancer and both cohorts will undergo testing with the 21 gene RS.
General Inclusion Criteria (All Patients)
- Age 18 years of age or older
- ER Positive Tumours (≥1% positive cells or Allred score ≥ 2 (Appendix 1))
- Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer (0-1 by IHC or FISH <2.0)
- No evidence of metastatic disease on CT, bone scan or other imaging
- Fit for consideration of chemotherapy as determined by the Investigator
- Adequate performance status (Eastern Cooperative Oncology Group (ECOG) 0 or 1 (Appendix 2))
Inclusion Criteria - Cohort 1 (Postoperative Patients): N= 75
- Adequate surgical excision of breast tumour (mastectomy or lumpectomy) and lymph nodes (sentinel lymph biopsy or axillary dissection)
- Any tumour size (T stage (Appendix 3))
- Involvement of 1-3 lymph nodes (N1, including micrometastases)
Inclusion Criteria - Cohort 2 (Preoperative Patients): N= 75
- Candidates for preoperative therapy for early breast cancer
- T2-T4 tumours
- Involvement of at least one lymph node, (including micrometastases) on biopsy
- Adequate tissue from core biopsy for 21 gene RS testing (approximate minimum 5mm)
Exclusion Criteria (All patients):
- ER negative tumour (Allred score 0-1)
- HER2 positive tumours as defined by IHC 3+ or FISH ≥ 2.0
- Node negative disease, including those with Isolated tumour cells only (node negative i+/i-)
- Known metastatic breast cancer
- Performance status ≥ 2
- Patients not considered by their treating physician to be fit to undergo chemotherapy.
- Men with breast cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03843346
|Letterkenny University Hospital|
|Letterkenny, Co. Donegal, Ireland|
|St Vincent's University Hospital|
|Dublin, Dublin 4, Ireland|
|Mater Misericordiae University Hospital & Mater Private Hospital|
|Dublin, Dublin 7, Ireland|
|Dublin, Dublin 9, Ireland|
|Bon Secour Cork|
|Cork University Hospital|
|St James' Hospital|
|University Hospital Galway|
|University Hospital Limerick|
|Limerick, Ireland, V94 F858|
|University Hospital Waterford|
|Principal Investigator:||Dr Patrick Morris||Beaumont Hospital|
|Responsible Party:||Cancer Trials Ireland|
|Other Study ID Numbers:||
|First Posted:||February 18, 2019 Key Record Dates|
|Last Update Posted:||January 18, 2022|
|Last Verified:||January 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms by Site